Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Seckinger

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 13